[go: up one dir, main page]

AU1168099A - Formulations comprising dissolved paroxetine - Google Patents

Formulations comprising dissolved paroxetine Download PDF

Info

Publication number
AU1168099A
AU1168099A AU11680/99A AU1168099A AU1168099A AU 1168099 A AU1168099 A AU 1168099A AU 11680/99 A AU11680/99 A AU 11680/99A AU 1168099 A AU1168099 A AU 1168099A AU 1168099 A AU1168099 A AU 1168099A
Authority
AU
Australia
Prior art keywords
paroxetine
solid
carrier
capsule
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11680/99A
Other languages
English (en)
Inventor
Ahmad Ghazawi
Graham Stanley Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU1168099A publication Critical patent/AU1168099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU11680/99A 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine Abandoned AU1168099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9724544 1997-11-21
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
PCT/GB1998/003471 WO1999026625A1 (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Publications (1)

Publication Number Publication Date
AU1168099A true AU1168099A (en) 1999-06-15

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11680/99A Abandoned AU1168099A (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Country Status (24)

Country Link
EP (1) EP1033986A1 (es)
JP (1) JP2001523718A (es)
KR (1) KR20010032320A (es)
CN (1) CN1279608A (es)
AP (1) AP2000001821A0 (es)
AR (1) AR015485A1 (es)
AU (1) AU1168099A (es)
BG (1) BG104527A (es)
BR (1) BR9814220A (es)
CO (1) CO4970832A1 (es)
DZ (1) DZ2658A1 (es)
EA (1) EA200000552A1 (es)
GB (1) GB9724544D0 (es)
HU (1) HUP0100580A3 (es)
IL (1) IL136106A0 (es)
MA (1) MA24704A1 (es)
NO (1) NO20002590L (es)
OA (1) OA11385A (es)
PE (1) PE20000381A1 (es)
PL (1) PL340555A1 (es)
SK (1) SK7342000A3 (es)
TR (1) TR200001423T2 (es)
WO (1) WO1999026625A1 (es)
ZA (1) ZA9810637B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
ATE311883T1 (de) 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
CA2341984A1 (en) 1999-07-01 2001-01-11 Paolo Mascagni Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US7011846B2 (en) * 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9707585A (es) * 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
SK95099A3 (en) * 1997-01-15 2000-01-18 Smithkline Beecham Plc Process for the preparation of free-flowing form of paroxetine hydrochloride, pharmaceutical composition containing same and use thereof

Also Published As

Publication number Publication date
GB9724544D0 (en) 1998-01-21
TR200001423T2 (tr) 2000-10-23
HUP0100580A3 (en) 2002-05-28
MA24704A1 (fr) 1999-07-01
PL340555A1 (en) 2001-02-12
SK7342000A3 (en) 2000-12-11
BR9814220A (pt) 2001-12-26
KR20010032320A (ko) 2001-04-16
PE20000381A1 (es) 2000-05-07
CN1279608A (zh) 2001-01-10
IL136106A0 (en) 2001-05-20
AR015485A1 (es) 2001-05-02
DZ2658A1 (fr) 2003-03-22
AP2000001821A0 (en) 2000-06-30
BG104527A (en) 2001-04-30
OA11385A (en) 2004-01-27
WO1999026625A1 (en) 1999-06-03
NO20002590L (no) 2000-07-19
HUP0100580A2 (hu) 2002-04-29
ZA9810637B (en) 2000-05-22
JP2001523718A (ja) 2001-11-27
CO4970832A1 (es) 2000-11-07
NO20002590D0 (no) 2000-05-19
EP1033986A1 (en) 2000-09-13
EA200000552A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
US6596308B2 (en) Controlled release pharmaceutical composition
AU2006311818B9 (en) Improved delivery of tetrahydrocannabinol
TWI490216B (zh) 用作ｃ型肝炎病毒蛋白酶抑制劑之醫藥組合物
US6491950B1 (en) Controlled release pharmaceutical composition
CA2627351C (en) Lipophilic vehicle-based dual controlled release matrix system
DK170209B1 (da) Ranitidinholdigt kapselpræparat og ikke-vandigt flydende præparat
AU2016203127B2 (en) An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
AU1168099A (en) Formulations comprising dissolved paroxetine
WO2021163023A1 (en) Stable formulations of dronabinol
CA2656540A1 (en) Ibuprofen-containing liquid filled hard capsules
KR100679582B1 (ko) 경질 쉘 캡슐용 이부프로펜 용액
AU2013213706B2 (en) An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20020032220A1 (en) Formulations comprising dissolved paroxetine
JP6572244B2 (ja) 味覚マスキング薬製剤
CA2310407A1 (en) Formulations comprising dissolved paroxetine
US20040146537A1 (en) Oily wax matrix suspension formulation comprising pharmacologically active agents
MXPA00005030A (es) Formulaciones que contienen paroxetina disuelta
CZ20001876A3 (cs) Prostředky obsahující rozpuštěný paroxetin
KR20010078703A (ko) 신규 제약 제제

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted